- Home
- BATL vs GLTO Comparison
BATL vs GLTO Comparison
Compare BATL & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BATL | GLTO |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 23.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BATL | GLTO |
|---|---|---|
| Price | $1.16 | $22.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 76.2K | ★ 3.4M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $183,422,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $2.01 |
| 52 Week High | $3.67 | $33.60 |
Technical Indicators
Market Signals| Indicator | BATL | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | 64.85 |
| Support Level | $1.11 | $16.70 |
| Resistance Level | $1.15 | $29.03 |
| Average True Range (ATR) | 0.06 | 2.91 |
| MACD | 0.01 | -0.22 |
| Stochastic Oscillator | 50.00 | 48.08 |
Price Performance
Historical ComparisonAbout BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.